Last Updated: March, 2026
Trusted by 200+ Clients
Compare & Choose the Right Report Version for You
How to Order Your Report?
The report provides a detailed analysis essential for establishing a dactinomycin production plant. It encompasses all critical aspects necessary for dactinomycin production, including the cost of dactinomycin production, dactinomycin plant cost, dactinomycin production costs, and the overall dactinomycin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a dactinomycin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Dactinomycin is a potent anticancer antibiotic mainly used to stop the growth of fast-dividing cells in several types of tumours. It is primarily used in the treatment of childhood cancers, including Wilms’ tumour and certain muscle and bone cancers. It works by stopping the growth of cancer cells, which helps slow or prevent the spread of certain tumours. It is also used as part of combination therapy when stronger control of tumour growth is needed. It is also used as a drug in the treatment of cancers such as Wilms tumour, rhabdomyosarcoma, Ewing sarcoma, and gestational trophoblastic disease. The drug supports radiation treatment by making cancer cells more sensitive to targeted radiation, which allows better results in some cases. It is also used in managing certain pregnancy-related tumours where quick treatment is required to prevent further spread. In addition, it is sometimes used in the management of rare soft tissue cancers and certain pediatric cancers.
The primary factor that drives the market for dactinomycin is its demand as an antineoplastic agent in the medical field for chemotherapy treatment. Its application as an anti-cancer medicine for the treatment of solid tumours in children and choriocarcinoma in adult women significantly fuels its demand in the oncology centres and pharmaceutical industries. Its application as an intravenous antineoplastic antibiotic in combination with other chemotherapy drugs to improve treatment results further promotes its demand in the medical and healthcare sectors. Its demand in hospitals and specialised cancer care centres to help limit cancer cell activity and strengthen the overall treatment plan for intensive care patients also drives its market expansion. Industrial dactinomycin procurement depends on factors such as the cost and supply of fermentation-based raw materials, strict quality controls, and adherence to safety and regulatory standards linked to cytotoxic drugs. Production methods, supplier stability, waste-handling rules, and secure transport systems also shape global procurement patterns, as buyers focus on reliable batches for consistent treatment availability.
According to the dactinomycin production plant project report, the major raw materials for dactinomycin production includes Streptomyces parvulus.
The extensive dactinomycin production cost report consists of the following industrial production process:
Dactinomycin is also commonly known as Actinomycin D. It is a chromopeptide antibiotic produced by the bacterium Streptomyces parvulus. It appears as a bright red, somewhat hygroscopic, crystalline powder. The molecular formula of the compound is C62H86N12O16, and its molar mass is approximately 1255.42 g/mol. The compound has a melting point of approximately 241–243 degrees Celsius, at which it decomposes, and it is not flammable. The boiling point of the compound is around 848 degrees Celsius. It is soluble in water at 10 degrees Celsius, slightly soluble in water, and freely soluble in alcohol, dimethyl sulfoxide (DMSO) at 10 mg/mL and dimethylformamide (DMF) at 20 mg/mL. It is considered highly toxic and is extremely harmful if swallowed, inhaled, or absorbed through the skin. It is strongly recommended to wear protective clothing, gloves, and a face mask while handling this compound. Prolonged or repeated exposure to this substance may cause severe adverse health effects, including bone marrow suppression, liver damage (including sinusoidal obstruction syndrome), gastrointestinal ulcerations, renal impairment, and alopecia.
Dactinomycin Production Cost Report
Choose What's Right for You
Pay Via
| Particulars | Details |
|---|---|
| Product Name | Dactinomycin |
| Scope | Production Process: Process Flow, Material Flow, Material Balance Raw Material and Product Specifications: Raw Material Consumption, Product and Co-product Generation Land and Site Cost: Offsites/Civil Works, Equipment Cost, Auxiliary Equipment Costs, Contingency, Engineering and Consulting Charges, Working Capital Variable Cost: Raw Material, Utilities, Other Variable Costs Fixed Cost: Labor Requirements and Wages, Overhead Expenses, Maintenance Charges, Other Fixed Costs Financing Costs: Interest on Working Capital, Interest on Loans Other Costs: Depreciation Charges, General Sales and Admin Cost |
| Currency | US$ (Data can also be provided in the local currency) |
| Pricing and Purchase Options | Basic: US$ 2499 Premium: US$ 3499 Enterprise: US$ 4799 |
| Customization Scope | The report can be customized as per the requirement of the customer |
| Post-Sale Analysts Report | 10-12 weeks of post-purchase analyst support after report delivery for any queries from the deliverable |
| Delivery Format | PDF and Excel format through email (editable version in PPT/Word format of the report can be also provided on special request) |
At Procurement Resource, we not only focus on optimizing the should cost of production for dactinomycin but also provide our clients with extensive intel and rigorous information on every aspect of the production process. By utilising a comprehensive cost model, we help you break down expenses related to raw materials, labour, and technology, offering clear pathways to savings. We also assist in evaluating the capital expenditure (CAPEX) and operating expenses (OPEX), which are often measured as cost per unit of production, such as USD/MT, ensuring that your financial planning is aligned with industry benchmarks.
We offer valuable insights on the top technology providers, in-depth supplier database, and best manufacturers, helping you make informed decisions to improve efficiency. Additionally, we design the most feasible layout for your production needs, ensuring the entire process runs smoothly. By minimizing the cash cost of production, we ensure that you stay competitive while securing long-term profitability in the growing dactinomycin market. Partnering with Procurement Resource guarantees that every aspect of your production is cost-efficient, advanced, and tailored to your specific requirements.
Vishakha Agrawal
Lead - Social & Development Research
Delivering procurement intelligence and supply chain analytics across healthcare, FMCG, and chemicals sectors, with expertise in cost modeling, vendor mapping, and spend optimization to support data-driven sourcing decisions and procurement outcomes.
Need more help?
Still Need Help?
